244 related articles for article (PubMed ID: 11242520)
1. Sequence variations in the amino- and carboxy-terminal parts of the surface envelope glycoprotein of HTLV type 1 induce specific neutralizing antibodies.
Tallet B; Astier-Gin T; Moynet D; Londos-Gagliardi D; Guillemain B
AIDS Res Hum Retroviruses; 2001 Mar; 17(4):337-48. PubMed ID: 11242520
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel neutralization-inducing regions of the human T cell lymphotropic virus type I envelope glycoproteins with human HTLV-I-seropositive sera.
Desgranges C; Souche S; Vernant JC; Smadja D; Vahlne A; Horal P
AIDS Res Hum Retroviruses; 1994 Feb; 10(2):163-73. PubMed ID: 8198868
[TBL] [Abstract][Full Text] [Related]
3. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
4. A source of glycosylated human T-cell lymphotropic virus type 1 envelope protein: expression of gp46 by the vaccinia virus/T7 polymerase system.
Arp J; LeVatte M; Rowe J; Perkins S; King E; Leystra-Lantz C; Foung SK; Dekaban GA
J Virol; 1996 Nov; 70(11):7349-59. PubMed ID: 8892853
[TBL] [Abstract][Full Text] [Related]
5. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
Hadlock KG; Rowe J; Foung SK
J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
[TBL] [Abstract][Full Text] [Related]
6. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
7. Mapping of homologous, amino-terminal neutralizing regions of human T-cell lymphotropic virus type I and II gp46 envelope glycoproteins.
Palker TJ; Riggs ER; Spragion DE; Muir AJ; Scearce RM; Randall RR; McAdams MW; McKnight A; Clapham PR; Weiss RA
J Virol; 1992 Oct; 66(10):5879-89. PubMed ID: 1326649
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
Kuo CW; Mirsaliotis A; Brighty DW
J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of variable regions of the surface envelope glycoprotein of HTLV type I and identification of new major epitopes in the 239-261 region.
Londos-Gagliardi D; Dalibart R; Geoffre S; Dalbon P; Pouliquen JF; Georges-Courbot MC; Sainte-Foie S; Hajjar C; Georges AJ; Moreau JP; Guillemain B
AIDS Res Hum Retroviruses; 1996 Jul; 12(10):941-50. PubMed ID: 8798979
[TBL] [Abstract][Full Text] [Related]
10. Epitope mapping of human monoclonal antibodies recognizing conformational epitopes within HTLV type 1 gp46, employing HTLV type 1/2 envelope chimeras.
Hadlock KG; Yang Q; Rowe J; Foung SK
AIDS Res Hum Retroviruses; 2002 Jan; 18(1):57-70. PubMed ID: 11804557
[TBL] [Abstract][Full Text] [Related]
11. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
12. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
13. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
14. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
15. Antibodies directed against a variable and neutralizable region of the HTLV-I envelope surface glycoprotein.
Londos-Gagliardi D; Armengaud MH; Freund F; Dalibart R; Moze E; Huet S; Legrand E; Guillemain BJ
Leukemia; 1997 Apr; 11 Suppl 3():38-41. PubMed ID: 9209290
[TBL] [Abstract][Full Text] [Related]
16. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
17. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
[TBL] [Abstract][Full Text] [Related]
18. Cervicovaginal synthesis of IgG antibodies to the immunodominant 175-199 domain of the surface glycoprotein gp46 of human T-cell leukemia virus type I.
Bélec L; Georges-Courbot MC; Georges A; Mohamed AS; Londos-Gagliardi D; Hallouin MC; Hocini H; Guillemain B
J Med Virol; 1996 Sep; 50(1):42-9. PubMed ID: 8890040
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing activity and antibody reactivity toward immunogenic regions of the human T cell leukemia virus type I surface glycoprotein in sera of infected patients with different clinical states.
Astier-Gin T; Portail JP; Londos-Gagliardi D; Moynet D; Blanchard S; Dalibart R; Pouliquen JF; Georges-Courbot MC; Hajjar C; Sainte-Foie S; Guillemain B
J Infect Dis; 1997 Mar; 175(3):716-9. PubMed ID: 9041352
[TBL] [Abstract][Full Text] [Related]
20. Amino acid changes at positions 173 and 187 in the human T-cell leukemia virus type 1 surface glycoprotein induce specific neutralizing antibodies.
Blanchard S; Astier-Gin T; Tallet B; Moynet D; Londos-Gagliardi D; Guillemain B
J Virol; 1999 Nov; 73(11):9369-76. PubMed ID: 10516045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
